Liquid Biopsies Enter the Singaporean Clinic
Multi-cancer early detection (MCED) tests—blood-based assays that look for circulating tumour DNA and other cancer signals—have generated substantial commercial excitement but limited population-level evidence. In the second half of 2026, Singapore began a clinical study involving 1,000 people at elevated cancer risk due to genetic factors or pre-cancerous conditions, led by the National Cancer Centre Singapore. The study links participants to the national health database and tracks long-term cancer diagnoses and survival outcomes, moving beyond test accuracy to the question that matters for health systems: do these tests actually improve outcomes?
The Asian Evidence Gap
Most MCED validation studies have been conducted in Western, predominantly Caucasian populations. Professor Ravindran Kanesvaran, chairman of NCCS’s medical oncology division, has explicitly cautioned that the performance characteristics of these tests cannot simply be assumed to transfer to Asian populations with distinct cancer epidemiology and genetic architecture. This is not a minor caveat—it goes to the core of whether a test that performs well in one population will produce acceptable sensitivity and specificity in another.
Targeted Screening by Metabolic Risk
A parallel study, Cancer Risk Assessments and Early detection (CRAnE), takes a different approach. Led by Lee Kong Chian School of Medicine, it focuses on targeted screening and prevention for cancers linked to metabolic dysfunction—diabetes, hypertension, high cholesterol, and obesity—which elevate risk for colorectal, lung, and breast cancers. The study tests multi-cancer risk assessment methods in primary care, matching individuals to screening tests and prevention advice based on their combined genetic and metabolic risk profile.
Why Primary Care Is the Integration Point
The choice of primary care as the delivery setting is strategically significant. Genomic risk information is most useful when it reaches people before specialist referral, at the point where screening decisions and lifestyle interventions are discussed. If DNA-based risk stratification remains confined to hospital genetics clinics, its population impact will be limited. The CRAnE study explicitly recognises this by embedding risk assessment in primary care workflows rather than treating it as a downstream specialist activity.
The Limits of Technology Without Pathways
Both studies reflect a broader principle: the value of genomic screening depends on what happens after a result is generated. An MCED test that detects a cancer signal without a clear diagnostic and treatment pathway creates anxiety without benefit. A DNA-informed risk score that identifies elevated risk without accessible surveillance is similarly incomplete. Singapore’s dual-track approach—evaluating both a technology-driven liquid biopsy model and a risk-stratified primary care model—suggests that the country is testing not just assays but delivery systems.
What Comes After the Trial
The MCED study’s linkage to national health records is designed to generate the kind of longitudinal evidence that regulators and payers require before national adoption. MCED tests are not currently part of Singapore’s national cancer screening programme precisely because cost-effectiveness and population benefit remain unproven. The trial will not resolve every uncertainty, but it will produce Asian-specific data on a question that has so far been answered largely with Western evidence.
